TY - JOUR AU - Schwedt, T. J. PY - 2014 DA - 2014// TI - Chronic migraine JO - BMJ VL - 348 UR - https://doi.org/10.1136/bmj.g1416 DO - 10.1136/bmj.g1416 ID - Schwedt2014 ER - TY - JOUR PY - 2013 DA - 2013// TI - The International Classification of Headache Disorders, 3rd edition (beta version) JO - Cephalalgia VL - 33 UR - https://doi.org/10.1177/0333102413485658 DO - 10.1177/0333102413485658 ID - ref2 ER - TY - JOUR AU - Stewart, W. F. PY - 2010 DA - 2010// TI - Employment and work impact of chronic migraine and episodic migraine JO - J Occup Environ Med VL - 52 UR - https://doi.org/10.1097/JOM.0b013e3181c1dc56 DO - 10.1097/JOM.0b013e3181c1dc56 ID - Stewart2010 ER - TY - JOUR PY - 2018 DA - 2018// TI - Global, regional, and national burden of migraine and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 JO - Lancet Neurol VL - 17 UR - https://doi.org/10.1016/S1474-4422(18)30322-3 DO - 10.1016/S1474-4422(18)30322-3 ID - ref4 ER - TY - STD TI - Lipton, R.B. and S.D. Silberstein, Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache, 2015. 55 Suppl 2: p. 103–122; quiz 123-6 ID - ref5 ER - TY - JOUR AU - Lambru, G. PY - 2018 DA - 2018// TI - Emerging drugs for migraine treatment: an update JO - Expert Opin Emerg Drugs VL - 23 UR - https://doi.org/10.1080/14728214.2018.1552939 DO - 10.1080/14728214.2018.1552939 ID - Lambru2018 ER - TY - JOUR AU - Cameron, C. PY - 2015 DA - 2015// TI - Triptans in the acute treatment of migraine: a systematic review and network meta-analysis JO - Headache VL - 55 UR - https://doi.org/10.1111/head.12601 DO - 10.1111/head.12601 ID - Cameron2015 ER - TY - JOUR AU - Dodick, D. W. PY - 2019 DA - 2019// TI - Ubrogepant for the treatment of migraine JO - N Engl J Med VL - 381 UR - https://doi.org/10.1056/NEJMoa1813049 DO - 10.1056/NEJMoa1813049 ID - Dodick2019 ER - TY - JOUR AU - Goadsby, P. J. PY - 2019 DA - 2019// TI - Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine JO - Brain VL - 142 UR - https://doi.org/10.1093/brain/awz134 DO - 10.1093/brain/awz134 ID - Goadsby2019 ER - TY - JOUR AU - Tepper, S. J. PY - 2018 DA - 2018// TI - History and review of anti-calcitonin gene-related peptide (CGRP) therapies: from translational research to treatment JO - Headache VL - 58 UR - https://doi.org/10.1111/head.13379 DO - 10.1111/head.13379 ID - Tepper2018 ER - TY - JOUR AU - Diener, H. C. PY - 2014 DA - 2014// TI - CGRP as a new target in prevention and treatment of migraine JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70228-5 DO - 10.1016/S1474-4422(14)70228-5 ID - Diener2014 ER - TY - JOUR AU - Peters, G. L. PY - 2019 DA - 2019// TI - Migraine overview and summary of current and emerging treatment options JO - Am J Manag Care VL - 25 ID - Peters2019 ER - TY - JOUR AU - Scuteri, D. PY - 2019 DA - 2019// TI - Eptinezumab for the treatment of migraine JO - Drugs Today (Barc) VL - 55 UR - https://doi.org/10.1358/dot.2019.55.11.3069864 DO - 10.1358/dot.2019.55.11.3069864 ID - Scuteri2019 ER - TY - JOUR AU - Sacco, S. PY - 2019 DA - 2019// TI - European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-018-0955-y DO - 10.1186/s10194-018-0955-y ID - Sacco2019 ER - TY - JOUR AU - Tiseo, C. PY - 2019 DA - 2019// TI - How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice JO - J Headache Pain VL - 20 UR - https://doi.org/10.1186/s10194-019-1000-5 DO - 10.1186/s10194-019-1000-5 ID - Tiseo2019 ER - TY - JOUR AU - Ashina, M. PY - 2020 DA - 2020// TI - Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1) JO - Cephalalgia VL - 40 UR - https://doi.org/10.1177/0333102420905132 DO - 10.1177/0333102420905132 ID - Ashina2020 ER - TY - JOUR AU - Dodick, D. W. PY - 2014 DA - 2014// TI - Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial JO - Lancet Neurol VL - 13 UR - https://doi.org/10.1016/S1474-4422(14)70209-1 DO - 10.1016/S1474-4422(14)70209-1 ID - Dodick2014 ER - TY - JOUR AU - Smith, J. T. PY - 2016 DA - 2016// TI - Randomized, double-blind, placebo-controlled trial of ALD403, an anti-CGRP peptide antibody in the prevention of chronic migraine JO - Headache VL - 56 UR - https://doi.org/10.1111/head.12907 DO - 10.1111/head.12907 ID - Smith2016 ER - TY - JOUR AU - Lipton, R. B. PY - 2020 DA - 2020// TI - Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2 JO - Neurology VL - 94 UR - https://doi.org/10.1212/WNL.0000000000009169 DO - 10.1212/WNL.0000000000009169 ID - Lipton2020 ER - TY - JOUR AU - Liberati, A. PY - 2009 DA - 2009// TI - The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration JO - BMJ VL - 339 UR - https://doi.org/10.1136/bmj.b2700 DO - 10.1136/bmj.b2700 ID - Liberati2009 ER - TY - JOUR AU - Goadsby, P. J. PY - 2017 DA - 2017// TI - Pathophysiology of migraine: a disorder of sensory processing JO - Physiol Rev VL - 97 UR - https://doi.org/10.1152/physrev.00034.2015 DO - 10.1152/physrev.00034.2015 ID - Goadsby2017 ER - TY - JOUR AU - Xu, D. PY - 2019 DA - 2019// TI - Safety and tolerability of calcitonin-gene-related peptide binding monoclonal antibodies for the prevention of episodic migraine - a meta-analysis of randomized controlled trials JO - Cephalalgia VL - 39 UR - https://doi.org/10.1177/0333102419829007 DO - 10.1177/0333102419829007 ID - Xu2019 ER - TY - JOUR AU - Allan, B. PY - 2019 DA - 2019// TI - Prevail: an open-label phase 3 trial to evaluate the safety of eptinezumab administered intravenously in patients with chronic migraine JO - Headache VL - 59 ID - Allan2019 ER - TY - JOUR AU - Diener, H. C. PY - 2020 DA - 2020// TI - Eptinezumab for the prevention of episodic migraine JO - Arzneimitteltherapie VL - 38 ID - Diener2020 ER - TY - JOUR AU - Zhu, Y. PY - 2018 DA - 2018// TI - The efficacy and safety of calcitonin gene-related peptide monoclonal antibody for episodic migraine: a meta-analysis JO - Neurol Sci VL - 39 UR - https://doi.org/10.1007/s10072-018-3547-3 DO - 10.1007/s10072-018-3547-3 ID - Zhu2018 ER - TY - JOUR AU - Yang, Y. PY - 2020 DA - 2020// TI - Safety and efficacy of Ubrogepant for the acute treatment of episodic migraine: a meta-analysis of randomized clinical trials JO - CNS Drugs VL - 34 UR - https://doi.org/10.1007/s40263-020-00715-7 DO - 10.1007/s40263-020-00715-7 ID - Yang2020 ER - TY - JOUR AU - Gao, B. PY - 2019 DA - 2019// TI - Efficacy and safety of Rimegepant for the acute treatment of migraine: evidence from randomized controlled trials JO - Front Pharmacol VL - 10 UR - https://doi.org/10.3389/fphar.2019.01577 DO - 10.3389/fphar.2019.01577 ID - Gao2019 ER - TY - JOUR AU - Yang, Y. PY - 2020 DA - 2020// TI - Different doses of galcanezumab versus placebo in patients with migraine and cluster headache: a meta-analysis of randomized controlled trials JO - J Headache Pain VL - 21 UR - https://doi.org/10.1186/s10194-020-1085-x DO - 10.1186/s10194-020-1085-x ID - Yang2020 ER - TY - JOUR AU - Berger, A. PY - 2012 DA - 2012// TI - Adherence with migraine prophylaxis in clinical practice JO - Pain Pract VL - 12 UR - https://doi.org/10.1111/j.1533-2500.2012.00530.x DO - 10.1111/j.1533-2500.2012.00530.x ID - Berger2012 ER - TY - JOUR AU - Hepp, Z. PY - 2017 DA - 2017// TI - Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis JO - Cephalalgia VL - 37 UR - https://doi.org/10.1177/0333102416678382 DO - 10.1177/0333102416678382 ID - Hepp2017 ER -